公开(公告)号：US20140045835A1

公开(公告)日：2014-02-13

申请号：US14054459

申请日：2013-10-15

Applicant: Array BioPharma Inc.

Inventor： Shelley Allen ,  Robert Kirk DeLisle ,  Julie Marie Hicks ,  Erik James Hicken ,  Joseph P. Lyssikatos ,  Fredrik P. Marmsater ,  Mark C. Munson ,  John E. Robinson ,  Qian Zhao

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.

Abstract translation: 本文提供了通过向有需要的哺乳动物施用治疗有效量的式I化合物来治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病的方法：其中B，R1， R1a，R2，R3，R4，R5，R6，R7，R10和R11具有说明书中给出的含义。

公开(公告)号：US11247990B1

公开(公告)日：2022-02-15

申请号：US16893784

申请日：2018-12-05

Applicant: ARRAY BIOPHARMA INC.

Inventor： Shelley Allen ,  Mark Laurence Boys ,  Adam Cook ,  John Gaudino ,  Ronald Jay Hinklin ,  Ellen Laird ,  Oren T. McNulty ,  Andrew T. Metcalf ,  Brad Newhouse ,  John E. Robinson

IPC: C07D471/04 ,  C07D519/00

Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

公开(公告)号：US20200291039A1

公开(公告)日：2020-09-17

申请号：US16890663

申请日：2020-06-02

Applicant: Array BioPharma Inc. ,  Celgene Corporation

Inventor： Shelley Allen ,  Mark Laurence Boys ,  Mark J. Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  John Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Christopher F. Kraser ,  Ellen Laird ,  John E. Robinson ,  Tony P. Tang ,  Laurence E. Burgess ,  Robert Andrew Rieger ,  Jed Pheneger ,  Yoshitaka Satoh ,  Katerina Leftheris ,  Raj K. Raheja ,  Brydon L. Bennett

IPC: C07D487/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

公开(公告)号：US10730880B2

公开(公告)日：2020-08-04

申请号：US16212493

申请日：2018-12-06

Applicant: Array BioPharma Inc. ,  Celgene Corporation

Inventor： Shelley Allen ,  Mark Laurence Boys ,  Mark J. Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  John Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Christopher F. Kraser ,  Ellen Laird ,  John E. Robinson ,  Tony P. Tang ,  Laurence E. Burgess ,  Robert Andrew Rieger ,  Jed Pheneger ,  Yoshitaka Satoh ,  Katerina Leftheris ,  Raj K. Raheja ,  Brydon L. Bennett

IPC: A61K45/06 ,  C07D487/04 ,  A61K31/4985 ,  A61K31/5377

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

公开(公告)号：US08895550B2

公开(公告)日：2014-11-25

申请号：US14054459

申请日：2013-10-15

Applicant: Array BioPharma Inc.

Inventor： Shelley Allen ,  Robert Kirk DeLisle ,  Julie Marie Hicks ,  Erik James Hicken ,  Joseph P. Lyssikatos ,  Fredrik P. Marmsater ,  Mark C. Munson ,  John E. Robinson ,  Qian Zhao

IPC: A61K31/437 ,  A61K31/4353 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.

Abstract translation: 本文提供了通过向有需要的哺乳动物施用治疗有效量的式I化合物来治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病的方法：其中B，R1， R1a，R2，R3，R4，R5，R6，R7，R10和R11具有说明书中给出的含义。